Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125,140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies.
Xue J, He H, Lin Z, Wu Y, Lin Y, Zhao H, Salamone SJ, Huang Y, Yang Y, Fang W, Zhang Y, Hong S, Ma Y, Zhang L. Xue J, et al. Among authors: zhang l, zhang y. Cancer Chemother Pharmacol. 2022 Sep;90(3):229-237. doi: 10.1007/s00280-022-04456-w. Epub 2022 Aug 3. Cancer Chemother Pharmacol. 2022. PMID: 35922567 Clinical Trial.
A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer.
Chen G, Chen X, Zhang Y, Yan F, Fang W, Yang Y, Hong S, Miao S, Wu M, Huang X, Luo Y, Zhou C, Gong R, Huang Y, Zhou N, Zhao H, Zhang L. Chen G, et al. Among authors: zhang l, zhang y. Cancer Med. 2017 May;6(5):953-961. doi: 10.1002/cam4.1059. Epub 2017 Apr 4. Cancer Med. 2017. PMID: 28374971 Free PMC article.
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, Yang Q, Zhang L. Fang W, et al. Among authors: zhang l, zhang y. Lancet Oncol. 2018 Oct;19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9. Epub 2018 Sep 10. Lancet Oncol. 2018. PMID: 30213452 Clinical Trial.
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y, Fang W, Yang Y, Hou X, Huang Y, Zhao H, Hong S, Zhang L. Zhou Y, et al. Among authors: zhang l, zhang x. J Immunother Cancer. 2018 Dec 22;6(1):155. doi: 10.1186/s40425-018-0477-9. J Immunother Cancer. 2018. PMID: 30577837 Free PMC article.
125,140 results
You have reached the last available page of results. Please see the User Guide for more information.